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Acyl-ghrelin has various peripheral effects including the potential role in mediating cellular 
lipid removal and macrophage polarization. Previous reports are contradictory as to how 
glycaemia and acyl-ghrelin mediates lipid retention and inflammation within individuals with 
Type 2 diabetes (T2D). Our aim was to explore acyl-ghrelin levels and ghrelin expression in 
relation to lipid and inflammatory markers within an ex vivo human model, biopsied visceral 
adipose tissue.  
Results indicated that acyl-ghrelin was associated with a decline in key lipid homeostasis 
genes ABCG1 and LXRβ expression. Within T2D there was also a down regulation of these 
genes which was independent of acyl-ghrelin levels. Circulatory pro-inflammatory markers 
(IL-6 and TNFα) had no association with ghrelin expression nor circulating acyl-ghrelin levels. 
Anti-inflammatory marker (IL-10) and total antioxidant status (TAOS%) were positively 
associated with ghrelin expression across samples from all groups combined (total sample 
cohort) and specifically within the obesity sample cohorts.  
Data supported the hypothesis that hyperglycaemia and acyl-ghrelin have a regulatory role 
in lipid retention. Furthermore, that both acyl- and desacyl-ghrelin is responsible for a 
protective inflammatory response; however this response is diminished in T2D. 







The metabolic syndrome has a strong association with developing Type 2 diabetes (T2D). 
This syndrome is characterised by elevated blood pressure and glucose levels, abdominal 
adiposity and abnormal HDL-cholesterol or triglyceride levels [1]. Within the last decade, the 
orexigenic hormone ghrelin has gained scientific interest due to its association with the 
metabolic syndrome. Secreted from the X/A-like cells of the oxyntic glands of the gastric 
fundus, the 28 amino acid protein undergoes post-translational octanoylation to produce 
acyl-ghrelin (AG), which binds to growth hormone secretagogue receptors; 1α (GHSR1α) and 
1β (GHSR1β) [2-4]. The unique post-translational modification of desacyl-ghrelin (DAG) into 
AG is dependent upon the bioavailability of a key octanoylation agents and de-octanoylating 
agent:- ghrelin O-acyltransferase (GOAT) and acyl-protein thioesterase 1 (APT1), 
respectively [5-7]. AG is often referred to as the active form, however recent studies suggest 
an independent role in homeostatic regulation for DAG [8-10]. Ghrelin has been reported to 
be present throughout the human body, indicative of a global homeostatic role, including an 
association with lipid and endocrine homeostasis [11, 12].   
 
Acyl-ghrelin & lipogenesis 
Peroxisome proliferator-activated receptor γ (PPARy) induces the removal of cellular lipids 
by high density lipoproteins via the activation of liver X receptor isoform β (LXRβ) and in 
turn, ATP binding cassette G1 (ABCG1). The relationship between AG, lipid retention and 
lipid biosynthesis, is unclear within published studies discussed in detail within previous 
review [13]. This may be due to variations in dose and route of AG administration and 
evidence for a species-specific effect arising from murine data. Chronic intravenous 
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administration of centrally acting AG has been implicated in having a detrimental effect on 
the transcription of the PPAR-LXR-ABC pathway, resulting in increased white adipose tissue 
(WAT) depots in rodents [14]. Furthermore, AG administration is reported to activate the 
LXR-ABC pathway in a dose dependant manner in human THP-1 macrophages [15].  
 
Acyl-ghrelin & inflammation 
It is noted that AG and its target receptors (GHSR1α and GHSR1β) have been localized within 
various immune cells including macrophages, neutrophils and lymphocytes [16, 17]. 
Emerging evidence has linked GHSR1 presence to M1 and M2 macrophages, which might 
alter adipose tissue inflammation via macrophage polarization [18]. Alterations in 
macrophage polarization can result in changes in key pro-inflammatory cytokines such as 
TNFα and IL-6, and the anti-inflammatory cytokine IL-10 [19]. In addition to inflammatory 
markers, increased plasma levels of AG have been associated with a decrease in oxidative 
burden within obese subjects [20]. Furthermore, evidence linking AG to an increased 
adipose tissue mass may provide a plausible role for AG interaction within systemic 
oxidative stress, due to biomarkers of oxidative stress being correlated with fat 
accumulation [21, 22]. 
 
Acyl-ghrelin & endocrine homeostasis 
Peripheral AG has been shown to have a direct metabolic action that influences 
endopancreatic function, altering glucose diabetogenic action [23, 24]. In obese individuals 
with T2D, a decreased plasma level of combined AG and DAG is associated with an increase 
 5 
in abdominal adiposity and insulin resistance [25]. As previously mentioned, ghrelin’s 
homeostatic action may play a role in T2D through lipid and glucose metabolism cross-talk. 
An increase in hepatic free fatty acid (FFA) oxidation as a result of adiposity, triggers insulin 
resistance and increased glucose output [26]. An AG infusion in healthy volunteers has been 
shown to increase circulating FFA levels [27], which promotes insulin resistance and a 
decline in insulin sensitivity via an increase of FFA, physical stress and reactive oxygen 
species associated with adipocyte hypertrophy. In line with this, ghrelin mediated-lipid 
retention, inflammation and glucose homeostasis may contribute to the pathophysiology of 
T2D. However, little data has been published to support the interaction of AG, lipid 
retention, inflammation and glucose homeostasis in humans.  
 
Materials and Methods 
Sample collection 
30 human visceral adipose tissue (hVAT) samples categorised as; non-obese (BMI<30 kg/m2 
(NO [n=10])), obese (BMI > 30 kg/m2 (O [n=10])), and obese with T2D (BMI > 30 kg/m2, T2D 
diagnosis >6 months (OT2D [n=10])) were collected, with a corresponding fasting blood 
sample and additional clinical information (age, body weight, height, medical history and 
prescribed medication). All of which were collected within 24 hours prior of undergoing 
routine abdominal operations at Morriston and Singleton Hospitals, Swansea and after 
informed consent was retrieved. A hVAT biopsy was taken from the greater omentum 
during surgery and placed immediately into RNALater® (Ambion Inc, UK) to preserve tissue 
stability and RNA integrity. Analytical chemistries (glucose, total cholesterol, high density 
lipoproteins (HDL), low density lipoproteins (LDL) and triglycerides) were measured using 
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the Randox Daytona Plus and HbA1c measured using Tosoh GX HLC-723 (Tosoh Bioscience 
Ltd) from whole blood samples collected in Vacutainer™ EDTA-plasma tubes. 
Real Time-PCR gene expression analysis 
Expression of ghrelin axis and lipid profile genes were measured in hVAT samples. RNA was 
extracted using Qiagen™ Lipid extraction kits via standard manufacturers protocol. Reverse 
transcription was performed using 1000ng/µl of total RNA and reverse transcriptase kit 
(Ambion™) with oligo d(T) primers. Real Time-PCR was performed using SYBR Green 
chemistries on thermocycler (CFX connect; Biorad™). Primer sequences are reported in 
Table 1, for genes of interest analysed for exploration of ghrelin axis and lipid retention. The 
average CT value was taken from triplicate assays and normalised against the invariant 
expression of β-actin housekeeper gene. Result were analysed using the 2-ΔΔCT method to 
produce relative fold change values in comparison between groups, standard error of the 
mean (SEM) was calculated from the average CT value for each sample produced within the 
experiment cohort. Fold change range of -1.5 to 1.5 is indicative of no overall change in 
gene expression levels.  
Measure of plasma acyl-ghrelin  
AG was measured in plasma taken from whole blood sample treated with an irreversible 
serine protease inhibitor, 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride (AESBF) 
[0.02mg/ml], using a Human Ghrelin (active) ELISA (Merck Millipore™) following the 
manufacturer instructions.  The complete assay was read at 450 nm and 590 nm absorbance 
on a SkanIt™ plate reader (ThermoScientific™).  
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Primer  Forward Primer  Reverse Primer  
Β-actin  GATGGCCACGGCTGCTTC  TGCCTCAGGGCAGCGGAA  
GHRL  TGAGCCCTGAACACCAGAGAG  AAAGCCAGATGAGCGCTTCTA  
PPARγ  ACAGCGACTTGGCAATATTTATTG  AGCTCCAGGGCTTGTAGCA  
ABCG1  TCCTATGTCAGGTATGGGTTCG  GTCCAGGTACAGCTTGGCAT  
LXRβ  CCTGCAGGTGGAGTTCATCA  CAGCTGGTCCTGCGGC  
LYPLA1  GGTCCTATCGGTGGTGCTAA  ACATCCATCATTTCCTGTTGACAC  
mBOAT4  TCTTTGTCTGAGCATGTGTGTAA  AAGCACTGGACCCTTGAACA  
Table 1. Primer sequences generated through NCBI primer tools and PrimerDesign  
Measure of plasma cytokine levels  
IL-6, TNFα and IL-10 were measured in fasting plasma taken from whole blood sample using 
ELISA (R&D systems™) following the manufacturer instructions.  The complete assay was 
read at 450 nm and 590 nm absorbance on a SkanIt™ plate reader (ThermoScientific™).  
Measure of total antioxidant status 
Relative total antioxidant status percentage (TAOS%) analysis was measured in plasma 
taken from whole blood sample. Plasma TAOS, which is inversely related to oxidative stress, 
was measured using the Sampson et al [28] protocol, a modification of Laight's photometric 
microassay and as published by Prior et al [29, 30].  
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Statistical analysis 
For gene expression data, statistical analysis (SPSS™; version 21) was run using one-way 
analysis of variance (ANOVA) on CT data normalised against β-actin housekeeper. All 
baseline characteristics were analysed using one-way ANOVA for parametric data and 
Kruskal Wallis for non-parametric data. Parametric data is given as mean and standard 
deviation shown in brackets. Non-paramteric data is presented as median and interquartile 
ranges [IQR] are shown in square brackets. Correlation analysis was performed using linear 
regression and Spearmans rank. P values less than 0.05 were deemed statistically significant. 
 
Results 
Total Sample Cohort 
Baseline characteristics were compared across all three groups indicating significant 
differences in key metabolic markers (Table 2). Within the total sample cohort, circulating 
acyl-ghrelin levels were associated with ΔCt values of GHRL expression (rs= -0.41, p<0.05), 
however, there was no association between circulating acyl-ghrelin levels and key 
octanoylation genes; LYPLA1 (rs= -0.01, p=0.62) or mBOAT4 (rs= -0.11, p=0.59). Baseline 
plasma acyl-ghrelin levels were significantly decreased in OT2D compared to both O 
(p<0.05) and NO groups (p<0.05) (Table 2). As shown in Figures 1A and 1B, acyl-ghrelin 
concentrations were inversely correlated with plasma glucose levels (rs=-0.41, p<0.05) and 
body weight (rs=-0.42; p<0.05), respectively. However, a positive correlation was seen when 
comparing plasma acyl-ghrelin levels with total cholesterol (rs = 0.38, p<0.05) and LDL (rs = 
0.39, p<0.05) (Figures 1C and 1D respectively). In the total sample cohort, there was no 
 9 
significant associations between inflammatory markers and plasma acyl-ghrelin (IL-6, rs= -
0.28, p=0.16; TNFα, rs= 0.02, p=0.96; IL-10, rs= 0.13, p=0.63; TAOS, rs= 0.26, p=0.19). 
However, when inflammatory markers were analysed against GHRL, increased gene 
expression or a decline in ΔCt value as shown, was associated with increased plasma IL-10 
(rs= -0.48, p<0.05) and TAOS% (rs= -0.40, p<0.05) and a non-significant reduction in TNFα (rs 
= 0.44, p=0.06). 
 
Non Obese    
(NO) 
(n=10) 
Obese                  
(O) 
(n=10) 






51.8 (15.5) 51.1 (12.0) 45.5 (6.8) 0.44 
Weight (Kg)* 
Median [IQR] 
72.2 [64-81] 90.7 [86-122] 131.4 [114-152] <0.001 
BMI (Kg/m2)* 
Median [IQR] 




4.8 [4.5-6.5] 5.4 [4.9-6.5] 6.7 [6.0-12.6] <0.01 
HbA1c (%)* 
Median [IQR] 




30.6 [26-39] 36.1 [30-37] 52.5 [36-68] <0.05 
Statin 
prescription#     
%  (n) 
20 (2) 10 (1) 50 (5) 0.11 
Acyl-ghrelin  
(pg/mL)*   
Median [IQR] 
467.2 [326-508] 515.5 [309-701] 228.5 [98-439] <0.05 
Table 2. Baseline characteristics for total sample cohort. Mean and standard deviation (SD) shown for normally 
distributed data & p-value determined using one-way ANOVA (Age; F(1,28)=0.58, p=0.44). * Median and 
interquartile range [IQR] shown for data that is not normally distributed and non-parametric Kruskal Wallis 
used for p-value determination. #Categorical data tested using Pearson Chi-square analysis. Significant p-value 
are shown in bold.  
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Figure 1. Scatter graphs showing correlations between AG levels and baseline characteristics. (A) Plasma 
glucose (R² = 0.113; p<0.05). (B) Body weight (R² = 0.2007; p<0.05). (C) Plasma total cholesterol  
(R² = 0.2301; p<0.05). (D) Plasma LDL (R² = 0.2437; p<0.05).  
 
Since the baseline characteristics showed a significant difference in weight between O and 
OT2D (p<0.05), the total cohort was split into two further groups for data analysis to enable 
the investigation and exploration of adiposity versus glycaemic state (i) obesity effect 
([OT2D+O] v NO) and (ii) diabetes effect ([O+NO] v OT2D). 
 
Obesity effect 
We observed that obese (OT2D+O) individuals had a significantly higher blood glucose 
concentration when compared to NO (6.1 [5.4-7.5] v 4.8 [4.5-5.7] mmol/L; p<0.05). Lipid 
profiles of total cholesterol (F (1,28)=0.6, p=0.45), HDL (F (1,28)=0.6, p=0.43), LDL (F 
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(1,28)=1.4, p=0.25) and triglycerides were unaltered (F (1,28)=2.3, p=0.14) (Figure 2A-
D)(Table 3). LXRβ, ABCG1, GHRL, mBOAT4, PPARγ and LYPLA1 gene expression showed no 
difference between obese (OT2D+O) and NO individuals (Figure 3A). Plasma AG showed no 
significant association with inflammatory cytokines within the obese group (IL-6, rs=0.14, 
p=0.59; TNFα, rs=0.26, p=0.47; IL-10, rs=0.18, p=0.63). Furthermore, inflammatory cytokines, 
IL-6 (rs=-0.03, p=0.92) and TNFα (rs=0.42, p=0.20) had no association with GHRL expression, 
However, the pro-inflammatory marker IL-10, demonstrated a significant association with 
GHRL expression (rs=-0.57, p<0.05). Additionally, TAOS% indicates oxidative stress was also 
associated with GHRL expression (rs=-0.54, p<0.01), however, further down-stream when 




OT2D individuals, when compared with those with normoglycaemia (NO+O), were 
significantly different in weight (131.4 [116-148] v 82.0 [72-100] Kg: p<0.01), BMI (47.3 [43-
50] v 29.9 [43-50] Kg/m2; p<0.01), plasma glucose (6.7 [6.0-11.1] v 5.3 [4.6-5.9] mmol/L: 
p<0.01) and HbA1c (7.0 [5.5-7.6] v 5.2 [4.6-5.6] %: p<0.01). Lipid profiles of total cholesterol 
(F (1,28)=9.5, p<0.01), HDL (F (1,28)=7.1, p<0.05) and LDL (F (1,28)=12.4, p<0.01) were 
significantly decreased in the OT2D group, while triglycerides showed a non-significant 
increase (F (1,28)=3.0, p=0.10)(Figure 2A-D). However, gene expression data for diabetes 
effect (OT2D) indicated a marked decrease in LXRβ, ABCG1 and GHRL expression levels 
(p<0.05) (Figure 3B). During analysis of inflammatory markers association with AG and GHRL 
gene expression, it was evident that within a diabetes effect all associations previously seen 
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had been diminished. AG showed no significant association with inflammatory cytokines (IL-
6; rs=-0.04, p=0.30, TNFα; rs=-0.60, p=0.29 and IL-10; rs=-0.70, p=0.19), nor with oxidative 
stress marker (TAOS%; rs=-0.42, p=0.23). In addition, GHRL expression had also diminished 
all associations with inflammatory and oxidative stress markers, showing no significant 
correlation with IL-6 (rs=-0.31, p=0.42), TNFα (rs=0.67, p=0.22), IL-10 (rs=0.82, p=0.09) or 
TAOS% (rs=-0.17, p=0.65). 
 
 
Figure 2. (A) Mean and standard error of total cholesterol levels (mmol/L) in comparison of control for the 
two-arm data analysis of obesity and diabetes effect. (B) Mean and standard error of LDL levels (mmol/L) in 
comparison of control for the two-arm data analysis of obesity and diabetes effect. (C) Mean and standard 
error of triglycerides levels (mmol/L) in comparison of control for the two-arm data analysis of obesity and 
diabetes effect. (D) Mean and standard error of HDL levels (mmol/L) in comparison of control for the two-arm 
data analysis of obesity and diabetes effect. P value determined using one-way ANOVA. * p <0.01. ** p <0.05.  
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  Non-Obese (NO) Obese (O) Obese Type 2 (OT2D) P-value 
Cholesterol 
(mmol/L)  
4.4 (1.2)  4.8 (1.7)  3.1 (0.7)  <0.05  
HDL          
(mmol/L)  
1.1 (0.4)  1.3 (0.8)  0.7 (0.2)  <0.05  
LDL          
(mmol/L)  
2.7 (0.9)  2.8 (1.1)  1.5 (0.5)  <0.01  
Triglycerides 
(mmol/L)  
1.2 (1.0)  1.5 (0.6)  1.9 (0.8)  0.19  
Table 3. Mean and standard deviation shown for lipid profiles for total cohort. Mean and standard deviation 
shown for normally distributed data & p-value determined using one way ANOVA. Significant values are shown 
in bold.  
 
Figure 3. Relative fold change values for gene expression data; negative fold change indicates down-regulation, 
positive fold change indicates up-regulation and fold change between -1.5 and 1.5 is classed as no fold change, 
indicated by shaded area. (A) Obesity effect (NO v [O+OT2D]). (B) Diabetes effect ([NO+O] v OT2D). * indicates 
statistical significance (p<0.05) between ΔCt values between sample cohort for gene of interest. 
 
Discussion 
To date, pre-clinical studies into the regulation of lipid homeostasis via the ghrelin axis have 
yielded contradictory findings. The translation of these studies to humans suggests ghrelin is 
a mediator of lipid homeostasis, at least in hVAT. Correlation of AG with key lipid profile 
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markers advocates that in a high AG environment there is an increase in plasma lipid 
profiles. These findings are consistent with published data in humans, in the presence of low 
AG, suggesting there is a diminished LXR-ABC response [15], which could result in an 
increase in cellular lipid retention. However, it is important to acknowledge the significance 
of cell specific responses, and due to the complex make-up of hVAT it merely represents the 
profile of gene expression in adipose tissue. The down regulation of LXRβ within the 
diabetes cohort (OT2D) could indicate that AG promotes an altered immune function, as LXR 
isoforms have an anti-inflammatory response [31]. In accordance with published data, 
individuals with T2D have a significantly decreased level of circulating AG [25], which 
appears to be dependent on plasma glucose levels. With increased endogenous glucose 
levels present in those with T2D already shown to increase lipid concentrations within the 
cell, data suggests the cellular export mechanism that counterbalances the lipid increase is 
impaired due to the lack of AG present. These findings correspond to the observed low 
plasma lipid concentrations due to detainment, trapping lipids within the cell, and lowering 
the rate of release into the circulation, independently of statin usage. 
Upon elucidation of a diabetes versus obesity effect, it is apparent that both obesity and 
T2D caused a marked decline in anti-inflammatory markers i.e. plasma IL-10 [32, 33], and an 
increase in surrogate oxidative stress markers  i.e. TAOS levels [29, 34]. Furthermore, within 
both the total sample and obese effect cohorts, there was a significant association between 
GHRL expression and IL-10. However, when explored within the diabetes effect cohort it 
was apparent this association was diminished. Improvements in both IL-10 and TAOS% 
levels were associated with the up regulation of GHRL expression, corresponding with 
published studies that indicate a promotion of inflammatory health in the presence of 
ghrelin [20, 35]. It is not determined whether this inflammatory protection is due to an 
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increase in both AG and DAG via increased GHRL expression, or whether is the result of a 
shift in DAG or AG concentrations. Previous studies have linked AG with a plausible role in 
protecting human lens epithelial cells [36] and osteoblastic cells [37] against reactive oxygen 
species accumulation. In addition to AG, DAG treatment has also established a protective 
role from oxidative stress in microvascular endothelial cells via regulation of sirtuin 1 (SIRT1) 
catalytic activity [38] and within osteoblastic cells independent of GHSR1α [37].  
Data demonstrates that circulatory AG concentration and action are dependent upon the 
mRNA expression of the GHRL gene. Furthermore, it is not altered due to the availability of 
APT1 or GOAT, with LYPLA1 and mBOAT4 gene expression remaining unchanged across the 
cohorts, respectively. However, an expansion of this analysis into the activity of the key des-
octanoylation and octanoylation genes may elucidate a regulatory role. Further work is key 
to the exploration of whether endogenous glucose levels within T2D effects the ratio of AG 
to DAG and how this effects hypertrophy and consequent comorbidities. 
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